ANI in Mumbai reported on September 29, 2021 that MSD Pharmaceuticals announced the launch of the Gardasil 9 Human Papillomavirus (HPV) vaccine to reduce the burden of HPV-related cancer in India.
Gardasil 9 is a 9-valent HPV vaccine that reduces cancers caused by the types of HPV in the vaccine in girls and women ages 9 to 26 and boys 9 to 15 years.
In addition, Gardasil 9 helps reduce cervical cancer, vulvar cancer, vaginal cancer and anal cancer in women.
The vaccine is also recommended in boys to prevent genital warts, anal intraepithelial neoplasias, anal cancer, and precancerous or dysplastic lesions.
MSD India Region General Manager Rehan A Khan added in a press release: “The introduction of GARDASIL 9 is a critical step in advancing the mission of building a healthy young India by reducing the burden of disease from HPV-related cancers and diseases in India the land is reduced. “
“HPV does not distinguish between men and women, so vaccination is a common practice for both boys and girls, and today nearly 25 countries recommend ‘gender-neutral vaccines’ programs to protect both sexes from infectious diseases.”
Gardasil 9 was first launched in the US in 2015 and approved in more than 80 countries around the world. The 4-valent vaccine Gardasil has been approved in India since 2008.
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., makes the vaccine Gardasil 9.